Hartmut Goldschmidt Selected Research

Lenalidomide (CC 5013)

1/2024	Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
11/2023	Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
10/2023	Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384).
10/2023	Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
9/2023	Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
4/2023	Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
11/2022	Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
6/2022	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
1/2022	MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
1/2022	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hartmut Goldschmidt Research Topics

Disease

249	Multiple Myeloma 12/2024 - 09/2002
52	Neoplasms (Cancer) 10/2023 - 12/2003
19	Amyloidosis 01/2023 - 12/2004
18	Immunoglobulin Light-chain Amyloidosis 01/2024 - 12/2003
18	Chromosome Aberrations (Chromosome Abnormalities) 01/2024 - 05/2008
14	Disease Progression 01/2024 - 06/2005
10	Paraproteinemias (Monoclonal Gammopathy) 01/2023 - 12/2003
10	Peripheral Nervous System Diseases (PNS Diseases) 08/2018 - 03/2009
9	Thrombocytopenia (Thrombopenia) 01/2023 - 08/2010
7	Residual Neoplasm 01/2024 - 09/2004
7	Neutropenia 01/2022 - 11/2011
7	Testicular Neoplasms (Testicular Cancer) 10/2017 - 04/2008
5	Renal Insufficiency (Renal Failure) 11/2022 - 11/2006
5	Smoldering Multiple Myeloma 01/2022 - 11/2018
5	Pneumonia (Pneumonitis) 11/2021 - 10/2013
5	Bone Diseases (Bone Disease) 05/2020 - 01/2011
5	Nausea 05/2020 - 07/2003
5	Anemia 01/2019 - 08/2010
5	Monoclonal Gammopathy of Undetermined Significance 11/2018 - 05/2008
5	Fatigue 10/2017 - 07/2004
4	Infections 12/2023 - 01/2019
4	Plasmacytoma 01/2017 - 03/2010
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2009 - 12/2003
3	Vomiting 05/2020 - 07/2003
3	Leukemia 07/2017 - 12/2003
3	Pain (Aches) 10/2013 - 01/2011
2	Hematologic Neoplasms (Hematological Malignancy) 10/2023 - 01/2002
2	Heart Arrest (Cardiac Arrest) 11/2022 - 10/2017
2	Septic Shock (Toxic Shock Syndrome) 11/2022 - 10/2017
2	Lymphopenia (Lymphocytopenia) 11/2021 - 01/2019
2	Leukopenia 07/2021 - 08/2010
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 12/2003
2	Trisomy (Trisomies) 01/2019 - 04/2010
2	Hypertension (High Blood Pressure) 10/2017 - 01/2016
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2016 - 08/2006

Drug/Important Bio-Agent (IBA)

55	Dexamethasone (Maxidex)FDA LinkGeneric 01/2024 - 03/2004
45	Bortezomib (Velcade)FDA Link 01/2024 - 06/2005
44	Lenalidomide (CC 5013)FDA Link 01/2024 - 01/2009
20	Melphalan (Alkeran)FDA LinkGeneric 11/2022 - 12/2004
16	daratumumabIBA 01/2024 - 10/2016
16	Thalidomide (Thalomid)FDA Link 01/2021 - 09/2002
16	AntigensIBA 11/2018 - 03/2005
15	Proteins (Proteins, Gene)FDA Link 04/2023 - 12/2003
14	carfilzomibIBA 09/2023 - 01/2016
14	Amyloid (Amyloid Fibrils)IBA 01/2021 - 12/2003
10	Proteasome InhibitorsIBA 10/2023 - 03/2017
10	Monoclonal AntibodiesIBA 08/2023 - 05/2014
10	Immunomodulating AgentsIBA 08/2023 - 01/2009
10	pomalidomideIBA 09/2019 - 10/2013
7	Immunoglobulins (Immunoglobulin)IBA 12/2024 - 05/2006
6	Biomarkers (Surrogate Marker)IBA 11/2022 - 07/2005
5	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2024 - 01/2017
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2023 - 06/2012
5	Chimeric Antigen ReceptorsIBA 11/2021 - 12/2019
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2021 - 01/2003
4	isatuximabIBA 11/2023 - 01/2022
4	Bendamustine Hydrochloride FDA Link 08/2020 - 10/2008
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 05/2020 - 01/2017
4	plerixafor FDA Link 02/2015 - 08/2006
4	Peptides (Polypeptides)IBA 01/2013 - 04/2006
4	EnzymesIBA 01/2013 - 04/2008
4	Vincristine (Oncovin)FDA LinkGeneric 06/2012 - 03/2004
4	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 07/2009 - 04/2006
4	Heparin (Liquaemin)FDA LinkGeneric 05/2009 - 01/2002
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 05/2024 - 04/2004
3	elotuzumabIBA 11/2023 - 12/2017
3	EpitopesIBA 10/2023 - 07/2005
3	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2021
3	AntibodiesIBA 01/2022 - 01/2021
3	ixazomibIBA 11/2020 - 01/2019
3	Prednisone (Sone)FDA LinkGeneric 08/2020 - 05/2011
3	CreatinineIBA 01/2020 - 08/2010
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 03/2010
3	PanobinostatIBA 02/2018 - 01/2010
3	DNA (Deoxyribonucleic Acid)IBA 11/2015 - 03/2011
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2010 - 06/2007
2	ChromatinIBA 11/2023 - 10/2022
2	Immunoglobulin G (IgG)IBA 01/2022 - 07/2008
2	Immunoglobulin M (IgM)IBA 01/2022 - 02/2017
2	Immunoconjugates (Immunoconjugate)IBA 10/2021 - 01/2021
2	B-Cell Maturation AntigenIBA 01/2021 - 10/2020
2	idecabtagene vicleucelIBA 01/2021 - 01/2021
2	Sodium Fluoride (Ossin)FDA Link 05/2020 - 07/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2018 - 09/2006
2	Histone Deacetylase InhibitorsIBA 02/2018 - 01/2010
2	Alkylating AgentsIBA 01/2018 - 09/2013
2	MicroRNAs (MicroRNA)IBA 02/2017 - 11/2015
2	Vorinostat FDA Link 01/2016 - 10/2013

Therapy/Procedure

88	Therapeutics 01/2024 - 09/2002
51	Stem Cell Transplantation 10/2023 - 11/2003
32	Drug Therapy (Chemotherapy) 08/2023 - 01/2002
12	Immunotherapy 10/2023 - 04/2006
11	Transplantation 11/2022 - 12/2003
7	Heart Transplantation (Grafting, Heart) 11/2017 - 09/2005
7	Autologous Transplantation 06/2017 - 09/2004
6	Radiotherapy 10/2021 - 01/2003
5	Aftercare (After-Treatment) 01/2022 - 04/2008
4	Hematopoietic Stem Cell Transplantation 01/2023 - 12/2003
4	Hematopoietic Stem Cell Mobilization 10/2021 - 12/2014
4	Salvage Therapy 01/2020 - 07/2013